Friday, September 29, 2023

561.316.3330

Biotechnology News Magazine

Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RNA editing (“ADAR editing”) capability and PRISMTM platform advancements at upcoming scientific conferences.

These include the TIDES USA: Oligonucleotides & Peptide Therapeutics meeting and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place September 20-23, 2021 and September 26-29, 2021, respectively.

“The data we’ll present at this year’s TIDES USA and OTS meetings underscore the remarkable progress we continue to make with our pipeline and our platform. Through the resolution provided by stereochemical control, we have identified new ways to enhance the pharmacologic profiles of our candidates, including the application of PN backbone modifications,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “At OTS, we will also highlight our discovery-stage alpha-1 antitrypsin deficiency program, as well as our leading ADAR editing modality. These data continue to support our belief that Wave’s ADAR editing modality has best-in-class potential among RNA editing approaches due to its versatility and ability to produce precise and efficient editing in the liver and central nervous system.”

TIDES USA: Oligonucleotides & Peptide Therapeutics Meeting

  • Wednesday, September 22 at 5:00 p.m. EDT
    Exploring New Oligonucleotide Backbone Chemistries and Their Deployment to Improve the Properties of Stereopure Oligonucleotides (Chandra Vargeese, PhD, Chief Technology Officer at Wave Life Sciences)
    Oligonucleotide Discovery to Clinic & CMC Track: Nucleic Acid Chemical Modifications
  • Thursday, September 23 at 8:30 a.m. EDT
    Enhancing the Pharmacologic Profiles of CNS Targeting Therapeutic Oligonucleotides (Elena Dale, PhD, Senior Director, Head of CNS Biology at Wave Life Sciences)
    Oligonucleotide Discovery to Clinic & CMC Track: Oligonucleotides for CNS, Skin Cancer, NAFLD and Other Indications
  • Tuesday, September 21-Thursday, September 23
    Impact of Nitrogen-containing Backbone Linkages on Stereopure Antisense Oligonucleotides in the CNS (Yuanjing Liu, PhD, Principal Scientist at Wave Life Sciences)
    Poster Available On Demand and for Viewing During Exhibit Hours

17th Annual Meeting of the Oligonucleotide Therapeutics Society

  • Tuesday, September 28 at 12:45 p.m. EDT
    Chemically Optimized Stereopure Oligonucleotides Direct ADAR-mediated RNA Editing of SERPINA1 Transcripts, Yielding Functional Alpha-1 Antitrypsin Protein in a Mouse Model for Alpha-1 Antitrypsin Deficiency (Prashant Monian, PhD, Senior Scientist at Wave Life Sciences)
    Session VI: Genome and RNA Editing (On Demand)
  • Sunday, September 26-Wednesday, September 29
    A Versatile Platform for ADAR-mediated RNA Editing In Vivo in Preclinical Models (Chikdu Shivalila, PhD, Principal Scientist at Wave Life Sciences)
    Poster Available On Demand
  • Sunday, September 26-Wednesday, September 29
    Predicting Exon Criticality from Primary Protein Structure (Jigar Desai, PhD, Scientist II at Wave Life Sciences)
    Poster Available On Demand
  • Sunday, September 26-Wednesday, September 29
    In Vitro Models for the Assessment of Antisense Oligonucleotide Induced Hepatotoxicity (Xuena Lin, MD, previously Senior Scientist II at Wave Life Sciences)
    Poster Available On Demand
  • Sunday, September 26-Wednesday, September 29
    Impact of Nitrogen-containing Backbone Linkages on Stereopure Antisense Oligonucleotides in the CNS (Pachamuthu Kandasamy, PhD, Senior Director, Head of Medicinal Chemistry at Wave Life Sciences)
    Poster Available On Demand
  • Sunday, September 26-Wednesday, September 29
    Allele-selective Reduction of Rho P23H-mutant Rhodopsin Rescues Phenotype Associated with Retinitis Pigmentosa in Preclinical Models (Michael Byrne, PhD, Senior Director, In Vivo Biology and Ophthalmology at Wave Life Sciences)
    Poster Available On Demand

About PRISM™
PRISM is Wave Life Sciences’ proprietary discovery and drug development platform that enables genetically defined diseases to be targeted with stereopure oligonucleotides across multiple therapeutic modalities, including silencing, splicing and editing. PRISM combines the company’s unique ability to construct stereopure oligonucleotides with a deep understanding of how the interplay among oligonucleotide sequence, chemistry and backbone stereochemistry impacts key pharmacological properties. By exploring these interactions through iterative analysis of in vitro and in vivo outcomes and machine learning-driven predictive modeling, the company continues to define design principles that are deployed across programs to rapidly develop and manufacture clinical candidates that meet pre-defined product profiles.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine